Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.50 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.50 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.50 |
| ▸ | PNMT | P11086 | 1/20 | 0.50 |
| ▸ | CD44 | P16070 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD5 | P21918 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351986 | 1.00 | — | — | |
| SCHEMBL34906 | 1.00 | — | — | |
| SCHEMBL33555 | 1.00 | — | — | |
| Hydrogen Sulfide SCHEMBL7469110 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL21176564 | 0.96 | TSHR (0.67) | TSHRHTR2CCYP2A6CES1MAOB | |
| Ammonia Solution, Strong SCHEMBL330529 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL28647349 | 0.96 | — | — | |
| Bromide SCHEMBL917076 | 0.96 | — | — | |
| Water SCHEMBL1168306 | 0.96 | — | — | |
| SCHEMBL31294878 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778800-B1 | Methods of making supercapacitor cells and micro-supercapacitors | HRL LABORATORIES, LLC (US) | 2014-07-15 | — | — | US | claimed |
| US-8503161-B1 | Supercapacitor cells and micro-supercapacitors | HRL LABORATORIES, LLC (US) | 2013-08-06 | — | — | US | claimed |
| US-7511100-B2 | Process for the production of crosslinked polymer employing low VOC-producing silane crosslinker and resulting crosslinked polymer | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2009-03-31 | — | — | US | claimed |
| WO-2024040076-A1 | EXTRACELLULAR VESICLE COMPRISING A BIOLOGICALLY ACTIVE MOLECULE AND A CELL PENETRATNG PEPTIDE CLEAVABLE LINKER | LONZA SALES AG (CH) | 2024-02-22 | — | — | WO | disclosed |
| US-9269927-B2 | Method and compound | CAMBRIDGE DISPLAY TECHNOLOGY, LTD. (GB) | 2016-02-23 | — | — | US | disclosed |
| US-20140364594-A1 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE | JNC CORP (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8901312-B2 | Cyclic compound, method for producing cyclic compound, and method for modifying biological molecule | JNC CORPORATION (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8778800-B1 | Methods of making supercapacitor cells and micro-supercapacitors | HRL LABORATORIES, LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140193937-A1 | METHOD AND COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2014-07-10 | — | — | US | disclosed |
| US-8503161-B1 | Supercapacitor cells and micro-supercapacitors | HRL LABORATORIES, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| WO-2013005026-A2 | POLYMERS, MONOMERS AND METHODS OF FORMING POLYMERS | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
| US-20130011901-A1 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE | JNC CORPORATION (JP) | 2013-01-10 | — | — | US | disclosed |
| EP-0416436-A1 | Filler containing thermoplastic mouldings | BASF Aktiengesellschaft (DE) | 1991-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364594-A1 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE | PTMS, CD38, TIMCC | TSHR 2131/4885HTR2C 3804/4885CYP2A6 1637/4885 |
| US-20130011901-A1 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE | PTMS, CD38, TIMCC | TSHR 2131/4885HTR2C 3804/4885CYP2A6 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.